Robert P. Mauch Sells 4,969 Shares of Cencora, Inc. (NYSE:COR) Stock

Cencora, Inc. (NYSE:COR - Get Free Report) CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. This represents a 9.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Cencora Stock Performance

Shares of COR stock traded up $3.66 during mid-day trading on Friday, hitting $286.05. 1,815,757 shares of the stock were exchanged, compared to its average volume of 1,520,659. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $296.65. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market capitalization of $55.47 billion, a price-to-earnings ratio of 40.69, a P/E/G ratio of 1.31 and a beta of 0.55. The stock's fifty day simple moving average is $268.09 and its two-hundred day simple moving average is $249.16.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. Cencora's dividend payout ratio (DPR) is currently 31.29%.

Hedge Funds Weigh In On Cencora

Several institutional investors have recently bought and sold shares of COR. JFS Wealth Advisors LLC raised its holdings in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares in the last quarter. Hoey Investments Inc. purchased a new position in shares of Cencora during the 1st quarter worth approximately $28,000. Banque Transatlantique SA purchased a new stake in shares of Cencora in the fourth quarter valued at approximately $29,000. SBI Securities Co. Ltd. acquired a new stake in Cencora in the fourth quarter valued at $30,000. Finally, Householder Group Estate & Retirement Specialist LLC boosted its position in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on COR. JPMorgan Chase & Co. increased their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Bank of America lifted their target price on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Morgan Stanley set a $288.00 price target on Cencora in a research report on Tuesday, April 15th. Finally, Wells Fargo & Company upped their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and an average target price of $284.55.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.